Autoimmunity and cancer

Masetti, Riccardo; Tiri, Alessandra; Tignanelli, Anna; Turrini, Elena; Argentiero, Alberto; Pession, Andrea; Esposito, Susanna

doi:10.1016/j.autrev.2021.102882

Cited by 21 publications

(16 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The link between autoimmunity and cancer is largely investigated but it is still controversial whether autoimmunity helps or blocks cancer set up or development [ 31 , 63 , 64 ]. Further investigations are needed to clarify also the potential therapeutic applications of drugs targeting autoimmunity.…”

Section: Discussionmentioning

confidence: 99%

Expression of Autoimmunity-Related Genes in Melanoma

Scatozza

Facchiano

2022

Cancers

View full text Add to dashboard Cite

(1) Background. Immune response dysregulation plays a key role in melanoma, as suggested by the substantial prognosis improvement observed under immune-modulation therapy. Similarly, the role of autoimmunity is under large investigation in melanoma and other cancers. (2) Methods. Expression of 98 autoimmunity-related genes was investigated in 1948 individuals (1024 melanoma and 924 healthy controls). Data were derived from four independent databases, namely, GEO in the selection phase, and Ist Online, GEPIA2 and GENT2, in three sequential validation-steps. ROC analyses were performed to measure the ability to discriminate melanoma from controls. Principal Component Analysis (PCA) was used to combine expression data; survival analysis was carried out on the GEPIA2 platform. (3) Results. Expression levels of NOD2, BAX, IL-18 and ADRB2 were found to be significantly different in melanoma vs. controls and discriminate melanoma from controls in an extremely effective way, either as single molecules (AUC > 0.93 in all cases) or as a profile, according to the PCA analysis. Patients showing high-expression of NOD2 and of IL-18 also show a significant survival improvement as compared to low-expression patients. (4) Conclusions. Four genes strongly related to autoimmunity show a significant altered expression in melanoma samples, highlighting the role they may play in melanoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of Autoimmunity-Related Genes in Melanoma

Scatozza

Facchiano

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…To illustrate this feature, we can cite: i) the generation of autoantibodies following tick bites [58] , ii) those to Factor V, induced for example, by second line antibiotics to treat iatrogenic infections [59] , [60] , iii) those induced by heparin therapy and platelet factor 4 (PF4) dependent, which can cause thrombocytopenia and thrombosis, iv) antibodies generated by treatments with a variety of other drugs [61] , [62] , [63] , [64] , v) anti-PF4 autoantibodies developed in vaccine induced thrombotic thrombocytopenia, occurring in very rare patients vaccinated with adenovirus-vector vaccines against SARS-Cov-2 [65] , [66] , vi) and autoimmune complications in cancer patients [67] , [68] . This list is obviously not exhaustive.…”

Section: Other Potential Causes Of Autoantibodies Generationmentioning

confidence: 99%

Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes

Amiral¹,

Seghatchian²

2023

Transfusion and Apheresis Science

View full text Add to dashboard Cite

“…Although possible mechanisms for tumor incidence in systemic rheumatic diseases have been discussed in each section above, several potential mechanisms linking malignancies and rheumatic disease have been generally suggested up to now (9,95,96). Chronic inflammation and tissue damage induced by rheumatic disease, inability to clear viral oncogenic infections and certain therapies discussed above are related to malignancies secondary to rheumatic disease; while cancer-induced autoimmunity, treatments for cancer (immunotherapy, chemotherapy or radiation therapy) may contribute to the occurrence of rheumatic disease secondary to malignancies.…”

Section: Mechanisms Linking Malignancies and Rheumatic Diseasesmentioning

confidence: 99%

Malignancies in systemic rheumatic diseases: A mini review

Geng

Ye²,

Zhu³

2023

Front. Immunol.

View full text Add to dashboard Cite

There is an increased risk of malignancies in patients with many systemic rheumatic diseases, which negatively impact on their quality of life. The risk and types of malignancies can differ by the type of rheumatic diseases. Possible mechanisms linking them are dynamic and complicated, including chronic inflammation and damage in rheumatic disease, inability to clear oncogenic infections, shared etiology and some anti-rheumatic therapies. Although certain disease-modifying anti-rheumatic drugs (DMARDs) have been proved to be potentially carcinogenic, the majority of them were not associated with increased risk of most malignancies in patients with systemic rheumatic diseases.

show abstract

Autoimmunity and cancer

Cited by 21 publications

References 83 publications

Expression of Autoimmunity-Related Genes in Melanoma

Expression of Autoimmunity-Related Genes in Melanoma

Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes

Malignancies in systemic rheumatic diseases: A mini review

Contact Info

Product

Resources

About